<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03755154</url>
  </required_header>
  <id_info>
    <org_study_id>CL1-65487-002</org_study_id>
    <secondary_id>2018-004170-97</secondary_id>
    <nct_id>NCT03755154</nct_id>
  </id_info>
  <brief_title>Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Phase I, Open Label, Non-randomised, Non-comparative, Multi-center Study, Evaluating S65487, a Bcl-2 Inhibitor Intravenously Administered, in Patients With Relapse or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ADIR, a Servier Group company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first in human study is to assess safety, tolerability, Pharmacokinetic&#xD;
      (PK) and preliminary clinical activity and to estimate the Maximum Tolerated Doses (MTD(s))/&#xD;
      Recommended Phase 2 Doses (RP2D(s)) of S65487 as single agent administered intravenously&#xD;
      (i.v.) in adult patients with refractory or relapsed Acute Myeloid Leukemia (AML),&#xD;
      Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM) or Chronic Lymphocytic Leukemia (CLL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed in two parts: one part for dose escalation, one part for dose&#xD;
      expansion.The dose escalation part will be followed by expansion part at the MTD(s)/RP2D(s)&#xD;
&#xD;
      This study will utilize an adaptative Bayesian Logistic Regression model to guide dose&#xD;
      escalation and estimate the MTD(s) based on the Dose Limiting Toxicity (DLT) relationship(s)&#xD;
      for S65487 in the indications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicity (DLT)</measure>
    <time_frame>until the end of the first cycle (each cycle is 21days)</time_frame>
    <description>Safety criterion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of Adverse Events</measure>
    <time_frame>through study completion an average of 6 months</time_frame>
    <description>Safety and tolerability criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of Serious Adverse Events</measure>
    <time_frame>through study completion an average of 6 months</time_frame>
    <description>Safety and tolerability criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose reductions</measure>
    <time_frame>through study completion an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose interruptions</measure>
    <time_frame>through study completion an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>through study completion an average of 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic (PK) profile of S65487: Area Under the Curve (AUC)</measure>
    <time_frame>Ramp up period (before C1D1), Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 9 (one cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of S65487: Volume of distribution at steady-state (Vss)</measure>
    <time_frame>Ramp up period (before C1D1), Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 9 (one cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of S65487: total CLearance (CL)</measure>
    <time_frame>Ramp up period (before C1D1), Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 9 (one cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of S65487: terminal half-life (t½z)</measure>
    <time_frame>Ramp up period (before C1D1), Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 9 (one cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Best Response observed during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Proportion of patients in whom a complete response (CR) or a partial response (PR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Relapse or Refractory Acute Myeloid Leukemia</condition>
  <condition>Relapse or Refractory Non-Hodgkin Lymphoma</condition>
  <condition>Relapse or Refractory Multiple Myeloma</condition>
  <condition>Relapse or Refractory Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>S65487 - initial scheme</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S65487 - alternative scheme</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S65487- initial scheme</intervention_name>
    <description>S65487 is administered as single agent via i.v. infusion on a 3-week cycle.</description>
    <arm_group_label>S65487 - initial scheme</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S65487 - alternative scheme</intervention_name>
    <description>S65487 is administered in 3 infusion in the first week of cycle 1, via i.v. infusion over 30 minutes.</description>
    <arm_group_label>S65487 - alternative scheme</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with cytologically confirmed and documented de novo, secondary or&#xD;
             therapy-related AML, excluding acute promyelocytic leukaemia with relapsed or&#xD;
             refractory disease without established alternative therapy. Or patients with&#xD;
             measurable confirmed Multiple Myeloma (IMWG) with relapsed or refractory disease who&#xD;
             have previously received at least three lines of treatment and without established&#xD;
             alternative therapy. Or patients with histologically and measurable confirmed Non&#xD;
             Hodgkin Lymphoma defined as Diffuse Large B cell Lymphoma (DLBCL), Follicular Lymphoma&#xD;
             (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), High-Grade B cell&#xD;
             Lymphoma with relapsed or refractory disease who have received at least two lines of&#xD;
             therapy (including rituximab) and without established alternative therapy. Or patients&#xD;
             with Chronic Lymphocytic Leukemia (CLL) who have relapsed or are refractory (except&#xD;
             treatment failure), as defined per iwCLL, from venetoclax treatment and without&#xD;
             established alternative therapy.&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2.&#xD;
&#xD;
          -  For NHL, MM patients and CLL patients: haematological function (independent of any&#xD;
             growth factor support) based on the last assessment performed before inclusion,&#xD;
             defined as: absolute neutrophil count (ANC) ≥ 1 x 109/L, haemoglobin ≥ 8 g/dL,&#xD;
             platelet count ≥ 50 x 109/L for NHL and MM patients, platelet count ≥ 30 x 109/L for&#xD;
             CLL patients.&#xD;
&#xD;
          -  For AML patients: circulating Blood White Cell count (WBC count) &lt; 25 x 109/L (with or&#xD;
             without use of hydroxycarbamide) based on the last assessment performed before&#xD;
             inclusion.&#xD;
&#xD;
          -  Adequate renal function based on the last assessment performed before inclusion,&#xD;
             assessed as Glomerular Filtration Rate (GFR) using Modification of Diet in Renal&#xD;
             Disease (MDRD) Formula.&#xD;
&#xD;
          -  Adequate hepatic function based on the last assessment performed before inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, breastfeeding or possibility of becoming pregnant during the study.&#xD;
&#xD;
          -  Participation in another interventional study at the same time or another&#xD;
             interventional study requiring investigational treatment intake within 3 weeks or at&#xD;
             least 5 half-lives (whichever is longer) prior to the first S65487 administration.&#xD;
&#xD;
          -  Participant already enrolled in the study (informed consent signed) and has received&#xD;
             at least one dose of S65487.&#xD;
&#xD;
          -  Patients who have not recovered from toxicity of previous anticancer therapy,&#xD;
             including grade ≥ 2 non-hematologic toxicity, prior to the first IMP administration&#xD;
             (including peripheral neurotoxicity). Certain toxicities will not be considered in&#xD;
             this category (e.g. alopecia).&#xD;
&#xD;
          -  Patients refractory to a previous treatment with a Bcl-2 inhibitor.&#xD;
&#xD;
          -  For AML patients : Allogenic stem cell transplant within 3 months before the first IMP&#xD;
             administration and/or patients who still receive immunosuppressive treatment within 3&#xD;
             months before the first IMP administration and/or patients with active&#xD;
             Graft-versus-host disease within 3 months before the first IMP administration and/or&#xD;
             patient who receive donor lymphocyte infusion (DLI) within 3 months before the first&#xD;
             IMP administration.&#xD;
&#xD;
          -  For NHL, MM and CLL patients : Prior allogenic stem cell transplant before the first&#xD;
             IMP administration and/or Autologous stem cell transplant within 3 months before the&#xD;
             first IMP administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Institut de Recherches Internationales Servier Clinical Studies Department</last_name>
    <phone>+33 1 55 72 43 66</phone>
    <email>clinical.trial.management@servier.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Alfred</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Lille Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nantes Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad Navarra- Servicio de Hematología</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca- Servicio de Hematología (4a planta)</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe - Servicio de Hematología - Torre F - Planta 7</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Hospital</name>
      <address>
        <city>Bebington</city>
        <zip>L63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SSE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.servier.com/</url>
    <description>Find Results on Servier Clinical Trial Data website</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Dose-escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.&#xD;
Access can be requested for all interventional clinical studies:&#xD;
used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).&#xD;
where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.&#xD;
In addition, access can be requested for all interventional clinical studies in patients:&#xD;
sponsored by Servier&#xD;
with a first patient enrolled as of 1 January 2004 onwards&#xD;
for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After Marketing Authorisation in EEA or US if the study is used for the approval.</ipd_time_frame>
    <ipd_access_criteria>Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.</ipd_access_criteria>
    <ipd_url>https://clinicaltrials.servier.com/</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study-level clinical trial data</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

